Assessment Of Association Between APRI Score And FIB4 Score With Liver Fibrosis Among Diabetes Type 2 Patients In Medicine Department Of Sir Takhtsinhji Hospital Bhavnagar

This study is a Prospective Observational Study used to assess the association between APRI score and FIB4 score with Liver Fibrosis among Diabetes Type 2 patients in medicine department of Sir Takhtsinhji hospital Bhavnagar

•Diabetes Mellitus Type 2 is a chronic, metabolic disease characterized by elevated levels of blood glucose. This disease affect all body systems, including the liver.

•

•Hyperglycemia, mainly caused by insulin resistance, affects the metabolism of lipids, carbohydrates and proteins and can lead to non-alcoholic fatty liver disease(NAFLD), which can further progress to non-alcoholic steatohepatitis(NASH), cirrhosis and, finally, hepatocellular carcinomas(rarely).

•Routine screening for Liver fibrosis is not currently recommended for patients with diabetes or otherwise increased risk in the absence of elevated liver transaminases or other evidence for liver disease.

•

•This reflects a lack of adequate, evidence-based methods for Liver fibrosis screening and also uncertainties about how to effectively treat Liver Fibrosis once diagnosed.

•

•it will be important to continuously re-evaluate the cost-effectiveness of screening. Since the rate of progression from simple steatosis (NAFL) to steatosis with associated inflammation and fibrosis (NASH) appears to be quite low.

•

•Patients at low risk for advanced fibrosis are followed-up every 2 years by repeating liver enzymes and fibrosis scores,

•whereas those at intermediate or high risk need to be referred to specialists to exclude other chronic liver diseases, to better assess disease severity and possibly to initiate specific therapy.